As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the Technical Engagement stage of this appraisal will begin during the first half of February 2021 and we will write to stakeholders then about how they can contribute to this.